BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Intercept Pharmaceuticals, Dainippon Sumitomo deal

Intercept granted Dainippon Sumitomo exclusive rights in Japan and China to develop and commercialize obeticholic acid ( INT-747) for chronic liver disease. Dainippon plans to develop...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >